Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-09-27
2005-09-27
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S301000, C514S344000, C514S352000, C514S359000, C514S365000, C514S336000, C514S379000, C514S350000, C514S354000, C514S394000, C514S403000, C544S406000, C544S407000, C546S114000, C546S280400, C546S298000, C546S310000, C546S323000, C548S200000, C548S241000, C548S261000, C548S309700, C548S374100, C548S503000
Reexamination Certificate
active
06949556
ABSTRACT:
The present invention relates to compounds of general formula (I),wherein R1-R4have the meanings given in the specification, A is CH2, CHOH or CH—(C1-C3-alkyl), B and C are independently CH2or CH—(C1-C3-alkyl), and R5is an aryl or heteroaryl group optionally substituted by the substituents listed in the specification. The compounds are useful for the manufacture of medicaments for the treatment of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes or diabetes complications, nephropathy or retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, and restricted memory performance or a restricted ability to learn, or the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptives.
REFERENCES:
patent: 4192888 (1980-03-01), Bondinell et al.
patent: 0253357 (1988-01-01), None
patent: 0420064 (1991-04-01), None
patent: 0 467 614 (1992-01-01), None
patent: WO 96/01817 (1996-01-01), None
patent: WO 97/04775 (1997-02-01), None
patent: WO 97/04779 (1997-02-01), None
patent: WO 99/47153 (1999-09-01), None
patent: WO 00/03746 (2000-01-01), None
patent: WO 00/51970 (2000-09-01), None
patent: WO 01/85675 (2001-11-01), None
patent: WO 02/20530 (2002-03-01), None
Albrecht et al., Chem. Abstract 77:88182, 1972.
Cannon et al., Centrally Acting Emetics. 6. Derivatives of β-Naphthylamine and 2-Indanamine, Journal of Medicinal Chemistry, 1972, vol. 15, No. 4, 348-350.
Cannon et al., Rigid Amino Acids Related to α-Methyldopa, Journal of Medicinal Chemistry, 1974, vol. 17, No. 5, 565-568.
Cannon et al., Conformationally Restricted Congeners of Dopamine Derived from 2-Aminoindan, Journal of Medicinal Chemistry, 1982, 25, 1442-1446.
Colette, et al., Étude Des Nitrosochlorures De L'Indéne Et De Ses Homologues, Ann. Chim. 1976, p. 269-276.
Copinga et al., 2-Amido-8-methoxytetralins: A Series of Nonindolic Melatonin-like Agents, J. Med. Chem. 1993, 36, 2891-2898.
Peter A. Crooks, A new synthesis of 2-aminoindanes, Chemistry and Industry, Jun. 15, 1974, 495.
Devocelle et al., Alternative synthesis of the chiral atypical β-adrenergic phenylethanolaminotetraline agonist SR58611A using enantioselective hydrogenation, Tetrahedron Letters 40 (1999) 4551-4554.
Endres et al., Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase, Proc. Natl. Acad. Sci. USA, vol. 95, 8880-8885, Jul. 1998.
Hillver et al., (S)-5-Fluoro-8-hydroxy-2-(dipropylamino)tetralin: A Putative 5-HT1A-Receptor Antagonist, J. Med. Chem., 1990, 33, 1541-1544.
Itoh et al., The Syntheses and β-Adrenoceptor Activities of N-Substituted 2-Amino-5,6-dihydroxy-1,2,3,4-tetrahydro-1-naphthalenols, Chem. Pharm. Bull. 25(11) 2917-2928 (1977).
Li et al., Activation of Protein Kinase Cα and/or ε Enhances Transcription of the Human Endothelial Nitric Oxide Synthase Gene, Molecular Pharmacology, 53:630-637 (1998).
Malapel-Andrieu et al., Palladium-Catalyzed Reactions of Indolic Triflate with Allylic Alcohols, Tetrahedron Letters 39 (1998) 39-42.
Masui et al., Stereoselective Synthesis of 1,2-Amino Alcohols by Asymmetric Borane Reduction of α-Oxoketoxime Ethers, Tetrahedron Letters 39 (1998) 5195-5198.
Moroi, et al., Interaction of Genetic Deficiency of Endothelial Nitric Oxide, Gender, and Pregnancy in Vascular Response to Injury in Mice, The Journal of Clinical Investigation, vol. 101, No. 6, Mar. 1998, 1225-1232.
Nakayama, et al., T-786→C Mutation in the 5′ -Flanking Region of the Endothelial Nitric Oxide Synthase Gene Is Associated With Coronary Spasm, Clinical Investigation and Reports, 2864-2870 (1999).
Sessa et al., Chronic Exercise in Dogs Increases Coronary Vascular Nitric Oxide Production and Endothelial Cell Nitril Oxide Synthase Gene Expression, Circulation Research, 74(2):349-353, 1994.
Trillat et al., (-)-5-Methyl-8-hydroxy-(di-n-propylamino)tetralin: A new 5-HT1Areceptor antagonist, Eur. J. Med. Chem. 33 (1998) 437-444.
Tschaen et al., Asymmetric Synthesis of MK-0499, J. Org. Chem. 60 (1995) 4324-4330.
Varenne et al., Percutaneous Gene Therapy Using Recombinant Adenoviruses Encoding Human Herpes Simplex Virus Thymidine Kinase, Human PAI-1, and Human NOS3 in Balloon-Injured Porcine Coronary Arteries, Human Gene Therapy 11:1329-1339 (Jun. 10, 2000).
Windaus, Chem.Ber. 57 (1924) 1735-1737.
Ozaki et al., 5-Fluorouracil Derivatives XXIII. Synthesis and Antitumor Activities of 1-carbamoyl-5-fluorouracils Having Aromatic Ring, Chinese Journal of Chemistry, 1998, vol. 16, No. 2, 171-177.
Strobel Hartmut
Wohlfart Paulus
Aventis Pharma Deutschland GmbH
Knight Julie Anne
Parker III Raymond S.
Rao Deepak
LandOfFree
Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3385857